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Research
Xenoestrogens (XEs) are environmental 
  contaminants capable of mimicking the effects 
of endogenous estrogens, but usually not pre-
cisely. Thus, they can initiate more, different, 
and mistimed estrogen exposures that can lead 
to disruptions of estrogenic signaling (Watson 
et al. 2007b). XEs can enter the environ  ment 
as manufacturing or agricultural by-products; 
these common human exposures are associ-
ated with a variety of reproductive and neuro-
logic impairments (reviewed by Colborn 
2004; Hotchkiss et al. 2008; McKinlay et al. 
2008). One class of XEs includes a series of 
plastics monomers and detergents that are 
similar in structure. Bisphenol A (BPA), a 
monomer of polycarbonate plastics, is found 
in beverage bottles, canned food liners   
(50–100 nM), and epoxy dental sealants 
(Krishnan et al. 1993; Milligan et al. 1998; 
vom Saal and Hughes 2005). Nonylphenol 
(NP), also used in products of polymer manu-
facture, is additionally found in detergents, 
cleaning materials, and pesticides (Rudel 
et al. 2003). Many chlorinated pesticides 
[e.g., dieldrin, o´,p´-dichlorodiphenylethylene 
(DDE; an active metabolite of DDT), and 
endosulfan] can also behave as XEs. In addi-
tion, XEs break down slowly, so persistent 
deposits are found in the soil (Agency for 
Toxic Substances and Disease Registry 2002), 
thus exposing food supply plants and animals, 
which sub  sequently pass these exposures on 
to humans. Because XEs bioaccumulate in fat 
tissues, resulting in prolonged and escalating 
human exposures, the exposure levels causing 
deleterious health effects are actively debated.
Physiologic estrogens classically bind to the 
nuclear estrogen receptors ER-α and ER-β, 
eliciting transcription at genomic hormone 
response elements (Gruber et al. 2004). This 
process requires prolonged response times for 
synthesis and targeting of the macro  molecules 
responsible for the hormonal changes. 
However, estrogens binding to the membrane 
form of these receptors (mERs) (reviewed by 
Watson and Gametchu 1999) are capable of 
eliciting rapid responses via nongenomic sig-
naling and second-messenger systems at low 
(femtomolar to nanomolar) concentrations. 
Our laboratory previously demonstrated that 
XEs (Bulayeva and Watson 2004; Watson 
et al. 2005) and physiologic estrogens such as 
estradiol (E2), estrone (E1), and estriol (E3) 
(Watson et al. 2008) can act via mERs at very 
low concentration ranges in pituitary and 
breast cancer cells; these concentrations are far 
lower than those needed for classical nuclear 
responses. Thus, although physiologic estrogens 
such as E2, E1, E3, and environmental estrogen 
mimetics were long thought to be weak via the 
nuclear response pathway, we now know them 
to act quite potently via membrane-initiated 
response pathways (Watson et al. 2007a).
The dopamine transporter (DAT) is a selec-
tive transporter that primarily functions to stop 
dopamine signaling by removing dopamine 
(dopamine uptake) from the extra  cellular space 
after a stimulatory release of dopamine has 
occurred. Dopamine is subsequently brought 
into intracellular vesicles via vesicular mono-
amine transporters to protect it and maintain 
dopamine separation from other cellular mol-
ecules with which it might react. There it is 
stored for subsequent rapid signaling (reviewed 
by Torres et al. 2003). Estrogens and XEs may 
exert regulatory effects on multiple types of 
transporters (Toyohira et al. 2003). Our previ-
ous data have shown that E2 can affect both the 
DAT (Watson et al. 2006) and the serotonin 
transporter (Koldzic-Zivanovic et al. 2004) spe-
cifically, as shown by using selective inhibitors 
to measure the activity of these transporters.
Altered dopamine signaling is associ-
ated with specific pathological states such as 
Parkinson disease and schizophrenia, as well as 
drug addiction. Some studies have suggested a 
connection between XE exposures and altered 
dopamine signaling. High levels of endosulfan 
exposure (6 mg/kg for 22 days) resulted in 
decreased dopamine levels and impaired mem-
ory in Wistar rat pups (Lakshmana and Raju 
1994). Polychlorinated biphenyls are known 
to inhibit vesicular trafficking of dopamine 
at micro  molar concentrations and to reduce 
dopamine concentrations in rat synaptosomes, 
thereby resulting in increased extracellular dop-
amine (Bemis and Seegal 2004). Extremely 
high concentrations of BPA (above typical 
environmental contamination levels) cause 
rapid release of dopamine via the cyclic AMP/
PKA pathway and N-type Ca2+ channels in 
PC12 pheochromocytoma cells (Yoneda et al. 
2003). DDE, dieldrin, and endosulfan cause 
neuro  toxicity (Bornman et al. 2007; Kitazawa 
et al. 2001; Naqvi and Vaishnavi 1993) in 
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Ba c k g r o u n d: The effects of 17β-estradiol (E2) and xenoestrogens (XEs) on dopamine transport 
may have important implications for the increased incidence of neurologic dis  orders, especially in 
women during life stages characterized by frequent hormonal fluctuations. 
oB j e c t i v e: We examined low concentrations of XEs [dieldrin, endosulfan, o´,p´-dichloro  diphenyl-
ethylene (DDE), nonylphenol (NP), and bisphenol A (BPA)] for nongenomic actions via action of 
membrane estrogen receptors (ERs). 
Me t h o d s : We measured activity of the dopamine transporter (DAT) by the efflux of 3H-dopamine 
in nontransfected nerve growth factor–differentiated PC12 rat pheochromo  cytoma cells expressing 
membrane DAT, ER-α, ER-β, and G-protein–coupled receptor 30. We used a plate immuno  assay 
to monitor trafficking of these proteins. 
re s u l t s: All compounds at 1 nM either caused efflux or inhibited efflux, or both; each compound 
evoked a distinct oscillatory pattern. At optimal times for each effect, we examined different con-
centrations of XEs. All XEs were active at some concentration < 10 nM, and dose responses were all 
non  monotonic. For example, 10–14 to 10–11 M DDE caused significant efflux inhibition, whereas 
NP and BPA enhanced or inhibited efflux at several concentrations. We also measured the effects of 
E2/XE combinations; DDE potentiated E2-mediated dopamine efflux, whereas BPA inhibited it. In 
E2-induced efflux, 15% more ER-α trafficked to the membrane, whereas ER-β waned; during BPA-
induced efflux, 20% more DAT was trafficked to the plasma membrane. 
co n c l u s i o n s: Low levels of environmental estrogen contaminants acting as endocrine disruptors 
via membrane ERs can alter dopamine efflux temporal patterning and the trafficking of DAT and 
membrane ERs, providing a cellular mechanism that could explain the disruption of physiologic 
neurotransmitter function.
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in vivo and in vitro systems. These effects of 
XEs might be due in part to their estrogenic 
effects via the non  genomic signaling pathways, 
although this has not been tested.
We recently used nerve growth factor 
(NGF)-differentiated PC12 cells, a well-charac-
terized neuronal cell model, to demon  strate that 
E2 inhibits dopamine uptake (Watson et al. 
2006) and subsequently causes rapid dopamine 
efflux, primarily via the mER-α (Alyea et al. 
2008). Here we report that very low concen-
trations of XEs also cause efflux of dopamine 
via the DAT, displaying non  conventional 
dose–response patterns and altered time phas-
ing. We also show that combinations of the 
physiologic estrogen E2 with some XEs (which 
exposures of animals and humans often entail) 
can cause either potentiation or attenuation of 
E2-mediated dopamine efflux, depending on the 
estrogen mimetic coadministered. Finally, we 
report a functional link between the sub  cellular 
location of the ER subtypes and DAT resulting 
from BPA treatment compared with treatment 
with E2. These cellular events could explain the 
impact of XE exposures on dopamine efflux, 
including changes in neuro  transmission, and 
some forms of functional endocrine disruption 
associated with neuro  toxicity, especially in the 
context of diseases that are affected differentially 
between males and females.
Materials and Methods
Materials. We purchased fetal bovine serum 
(FBS) from Atlanta Biologicals (Lawrenceville, 
GA); equine serum from Gibco (Carlsbad, CA); 
3H-dopamine from PerkinElmer (Waltham, 
MA); Scintiverse II from Fisher (Pittsburgh, 
PA); DDE and endosulfan from Ultra 
Scientific (North Kingstown, RI); and ABC 
(avidin:biotinylated enzyme complex) with 
alkaline phosphatase, para-nitrophenol phos-
phate, and levamisole from Vector Laboratories 
(Burlingame, CA). All other compounds, if not 
specified in text, were obtained from Sigma 
Chemical Co. (St. Louis, MO).
PC12 cell culture. PC12 cells were grown 
in high-glucose, phenol red–free RPMI 1640 
medium containing 5% FBS and 5% equine 
serum. For all experiments, cells were trans-
ferred to medium supplemented with 0.5% 
4× charcoal-stripped FBS and 0.5% equine 
serum 48 hr before experimentation to mini-
mize the effects of endogenous hormones. To 
promote differentiation and up-regulate DAT 
and mER-α, 20 ng/mL NGF-β was also added 
for 48 hr. Cells of passages 61–64 were used 
for these studies.
Dopamine efflux assay. As described pre-
viously (Alyea et al. 2008), we adapted the 
method of Janowsky et al. (1998) to measure 
3H-dopamine efflux using selective inhibitors to 
define the transporter. We plated PC12 cells on 
poly-d-lysine (10 µg/mL)-coated 48-well plates, 
deprived of endogenous hormones. We added 
uptake buffer (25 mM HEPES, 120 mM NaCl, 
5 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 
1 µM pargyline, 2 mg/mL glucose) containing 
0.2 mg/mL ascorbic acid and 50 nM desipra-
mine (pH 7.4) with or without 1-(2-[bis(4-flu-
orophenyl)methoxy]ethyl)-4-(3-phenylpropyl) 
piperazine dihydro  chloride (GBR 1290) for 
60 min at 37°C. GBR 12909 (100 nM) was 
added for a 60-min preincubation to define 
selective efflux by DAT. 3H-Dopamine 
(20 nM) was loaded into the cells for 10 min 
before two washes in release buffer (25 mM 
HEPES, 120 mM NaCl, 5 mM KCl, 1.2 mM 
MgSO4, 1 µM pargyline, 2 mg/mL glucose, 
0.2 mg/mL ascorbic acid, and 50 nM desipra-
mine). We then added release buffer containing 
treatments with or without GBR 12909 and 
collected extra  cellular fluid at the indicated time 
points to assess efflux. Triplicate aliquots of 
each well were counted in 2 mL Scintiverse II 
scintillant using a Beckman LS600SE scintilla-
tion counter (Beckman Coulter Inc., Fullerton, 
CA) averaged to provide one sample (n = 1) 
per well. Specific efflux was defined by aver-
aging the disintegrations per minute due to 
efflux in the presence of desipramine and GBR 
12909, and then subtracting these values from 
the efflux observed with desipramine alone. 
We subtracted background (vehicle controls) 
matched for ethanol concentration and time 
from treatment groups and present the data as 
3H-dopamine efflux per 106 cells. Our rationale 
for using 1 nM E2 in combination with a range 
of concentrations for the XEs DDE and BPA 
was the prevalence of approximately 1 nM E2 
as a physiologic concentration of total circulat-
ing E2 to which XEs would likely be added.
Quantitative immunoplate assay. Briefly, 
PC12 cells were plated on poly-d-lysine 
(10 µg/mL)-coated 96-well plates at 5,000 
cells/well, as previously described (Watson 
et al. 2006). Differentiated, serum-deprived 
cells were washed with phosphate-buffered 
saline (PBS) for 5 min, and treatments were 
added in the above uptake buffer with 50 nM 
dopamine for the indicated time points. Cells 
were fixed for 30 min at room temperature 
with 50 µL 2% paraformaldehyde and 0.2% 
gluteraldehyde with or without NP-40 (nonyl-
phenol ethoxylate) for permeabilized and non-
permeabilized cells, respectively. Cells were 
then washed twice (5 min each) with PBS and 
blocked with 0.1% fish gelatin/PBS for 45 min 
at 22°C. We added diluted primary anti  bodies 
to ER-α (1:1,000; Mc-20 and sc-542; Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA), 
ER-β (1:1,500; clone 9.88, E1276; Sigma), 
G-protein–coupled receptor 30 (GPR30; 
1:1,000; NLS4271; Novus, Littleton, CO), or 
DAT (1:2,000; W-17, sc-33056; Santa Cruz 
Biotechnology) overnight at 4°C; substitution 
of 2 µg anti-clathrin antibody provided a con-
trol for cell permeabilization (Campbell and 
Watson 2001). Cells were washed three times 
in PBS, incubated in appropriate biotinylated 
secondary antibodies for 1 hr, and then washed 
three times before a 1-hr incubation with 
ABC-alkaline phosphatase solution. After cells 
were washed five times with PBS, the substrate 
para-nitrophenol phosphate plus 0.5 mM 
levamisole was added in 100 mM sodium 
bicarbonate solution for 50 min at 37°C. Plates 
were read at 405 nm absorbance (A405), rinsed 
and stained with 0.1% crystal violet for 30 min 
at room temperature, washed with double-
distilled H2O, and dried overnight. We read 
dye (extracted from each well with 50 µL 10% 
acetic acid) at A590 and used this to estimate 
cell number per well. Data are plotted as per-
centage of control levels (A405/A590).
Statistics. We repeated each experimental 
set three times on different cell preparations, 
and we report the number for each treatment 
in the figure legends. We used analysis of vari-
ance to indicate whether further testing of 
individual data points for significance from 
their control was warranted. We performed 
statistical analyses for all assays using SigmaStat 
software (Systat Software, Inc., Chicago, IL) 
and set statistical significance at p < 0.05.
Results
We have previously demonstrated that 10–9 M 
E2 causes rapid dopamine efflux of preloaded 
3H-dopamine from PC12 cells (Alyea et al. 
2008). Figure 1 shows time courses for E2 
compared with each XE that we studied at 
this concentration. Both E2 and diethyl  stil-
bestrol (DES) displayed peak dopamine efflux 
at 9–15 min, followed by a return to baseline. 
NP and BPA caused rapid dopamine efflux 
within 5 min, followed by a return to baseline 
for NP and inhibited dopamine efflux for BPA. 
The pesticides DDE, dieldrin, and endosulfan 
did not cause dopamine efflux, but dopamine 
efflux inhibition occurred as early as 1 min 
for dieldrin and 3 min for DDE and endo-
sulfan, followed by continuous baseline activ-
ity. Interestingly, our results suggest that the 
compounds that belong to the same functional 
use/chemical structure class [grouped as the 
pesticides (DDE, endosulfan, dieldrin), plastics 
compounds (BPA, NP), and E2 along with the 
pharmaceutical estrogen DES (considered to be 
largely equivalent in actions by genomic tests)] 
cause similar temporal and stimulatory/inhibi-
tory regulation of dopamine efflux. The rapid-
ity with which all tested compounds in these 
studies either cause or inhibit dopamine efflux 
implies that nongenomic actions are involved.
Extensive dose–response curves for each 
compound at optimal time points, including 
exposure-relevant or physiologic/treatment-
  relevant doses in the case of endogenous/phar-
maceutical estrogens, are important to assess 
both for practical applicability of the results 
and to fully characterize the non  genomic 
actions of XEs, which we have shown in the Alyea and Watson
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past to elicit nonconventional non  monotonic 
dose responses at low levels (Bulayeva et al. 
2002; Bulayeva and Watson 2004; Wozniak 
et al. 2005). At 9 min, E2 caused dopamine 
efflux at the lowest concentration tested 
(10–14 M) and at the higher but still physi-
ologic concentrations (10–10 to 10–8 M), 
but not at the intermediate concentrations 
(Figure 2A). Although all compounds exhib-
ited multiple dose-induced stages of dopamine 
efflux, DES, endosulfan, and BPA caused 
dopamine efflux inhibition at quite low con-
centrations at 9 min. NP and DES also caused 
efflux at some of the higher concentrations 
tested. We also tested E2, dieldrin, NP, and 
BPA dopamine efflux dose responses at 5 min 
(Figure 2B) to examine the different flux states 
caused by these compounds at optimally active 
response times (for enhancement or inhibi-
tion) for each. E2 inhibited dopamine efflux 
at 10–12 and 10–8 M. NP inhibited dopamine 
efflux at 10–13 M, followed by a large peak 
of dopamine efflux at 10–11 M and continu-
ing modest efflux through 10–10 to 10–9 M 
concentrations. Dieldrin inhibited dopamine 
efflux at both 10–14 and 10–9 M concentra-
tions, whereas all other concentrations did 
not modify activity from basal. Interestingly, 
10–14 M BPA at this time point caused a 
3-fold higher dopamine efflux than at any 
concentration or time point tested for E2.
Our previous results (Alyea et al. 2008) 
showed that ER-α is the predominant media-
tor of E2-mediated dopamine efflux, with some 
possible inhibitory contributions from ER-β 
and GPR30. Therefore, we next investigated 
the effects of E2 and BPA on the sub  cellular 
location of all known ER subtypes and the 
DAT itself in treated cells. We compared this 
with untreated levels (100%) at times and 
concentrations representing their maximum 
effects on efflux enhancement or inhibition. 
We assessed the membrane versus total cel-
lular levels of these proteins in our quantitative 
immuno  reactive plate assay (Figure 3), which 
uses the permeabilized status of the cells to dis-
tinguish these values (Campbell and Watson 
2001). At 9 min, a 10–9 M E2 treatment 
increased membrane levels of ER-α (a stimu-
lator of efflux at this time and concentration) 
and decreased membrane ER-β (an inhibi-
tor of this response), whereas total levels of 
these proteins declined in the cells (Figure 3A); 
the levels of GPR30 and DAT remained 
unchanged in both compartments. However, 
10–14 M BPA at 5 min (Figure 3B), which 
correlates with the highest level of dopamine 
efflux, did not change levels of membrane 
ER-α or ER-β (with very slight overall declines 
of these proteins) and slightly decreased mem-
brane GPR30. Interestingly, the most robust 
change in this scenario was an increased 
membrane level of DAT, which could itself 
explain increased dopamine-pumping capac-
ity. At 9 min, 10–12 M BPA (Figure 3C), a 
time point and concentration that inhibited 
dopamine efflux, caused trafficking of all three 
ERs and the DAT away from the plasma mem-
brane, the combination of which would be 
expected to diminish the ability of the cell to 
pump dopa  mine out. These results suggest that 
changes in BPA-mediated dopamine efflux are 
due to distinctly different mechanisms than 
E2-mediated changes in dopamine efflux.
In our natural environment, exposure to 
these compounds is combinatorial, due to 
not only the presence of multiple compounds 
simultaneously but also the presence of endog-
enous steroids. Therefore, we examined combi-
nations for a limited number of these cases by 
comparing single exposures with a physiologic 
dose of E2 versus combinations of E2 with 
DDE (Figure 4A) and BPA (Figure 4B) at 
multiple concentrations. Alone, DDE at 9 min 
dramatically inhibited dopamine efflux at all 
concentrations ≤ 10–11 M, whereas E2 caused 
dopamine efflux at 10–14 M and at ≥ 10–10 M 
(as shown previously in Figure 2A with dif-
ferent optimized scales for the response). In 
combination with 10–9 M E2, DDE caused 
dopamine efflux at 10–14 to 10–11 M and 
at 10–9 M, clearly different (enhancing the 
response) compared with either compound 
alone (Figure 4A). The combination mag-
nitude of the response was a 3-fold increase 
above DDE alone. The dose–response curve 
was thus shifted from inhibitory to a more 
than additive heightening of dopamine efflux. 
Interestingly, this was not the case with BPA 
in combination with E2 (Figure 4B), where we 
saw inhibition of dopamine efflux at all stimu-
latory concentrations for either compound 
alone. At 5 min, 10–14 M BPA caused the 
greatest level of dopamine efflux, which was 
substantially reversed by combination with 
10–9 M E2. Only 10–13 M BPA still caused 
efflux (slightly) in the presence of physio-
logic levels of E2, which was not significantly 
Figure 1. Effects of 10–9 M E2 (n = 18), DES (n = 23), DDE (n = 14), NP (n = 18), dieldrin (n = 14), BPA (n = 14), and endosulfan (n = 18) on the dopamine efflux time 
course. The 10–9 M E2 time course is reproduced from Alyea et al. (2008), with permission of Journal of Neurochemistry, and is included here for purposes of com-
parison. Values are means and SEs. Points above the zero point line indicate a positive efflux of dopamine from the cells. 
*p < 0.05 compared with control. #p < 0.05 compared with E2 treatment. 
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different from BPA or E2 alone at that concen-
tration. Therefore, these two different XEs in 
combination with E2 altered dopamine efflux 
states compared with their singular effects in 
dramatically different ways.
Discussion
Epigenetic events caused by unknown neuro-
toxins have been implicated in initiating 
malfunction and degeneration of dopaminer-
gic neurons, and many have speculated that 
environmental contaminants such as XEs are 
linked to the increasing incidence of neuro-
logic diseases and dis  orders (Colborn 2004; 
Prasad et al. 1999). This is the first study to 
examine the non  genomic estrogenic effects of 
Figure 2. Concentration-dependent dopamine efflux patterns for E2 and XEs at 9 (A) and 5 min (B), using optimal time points for each compound chosen from the 10–9 M 
time course (Figure 1). (A) A 9-min dopamine efflux for E2, DES, endosulfan, DDE, NP, and BPA at concentrations ranging from 10–14 to 10–9 M. (B) A 5-min dopamine 
efflux for E2, dieldrin, NP, and BPA at concentrations ranging from 10–14 to 10–9 M. Values are means and SEs; numbers per treatment are as follows: E2, n = 18; dieldrin, 
n = 12; DES, n = 18; endosulfan, n = 12; DDE, n = 12; BPA, n = 23; NP, n = 15. Points above the zero point line indicate a positive efflux of dopamine from the cells. 
*p < 0.05 compared with control. #p < 0.05 compared with E2 treatment. 
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Figure 3. Quantitative plate assay measuring immunoreactive protein levels for plasma membrane and total ER-α, ER-β, GPR30, and DAT after treatment with 
E2 for 9 min (A), or BPA for 5 (B) or 9 min (C). (A) 10–9 M E2 for 9 min (dopamine efflux was significantly increased at this time point and concentration). (B) 10–14 M 
BPA for 5 min (DA efflux was significantly increased at this time point and concentration). (C) 10–12 M BPA for 9 min (DA efflux was significantly inhibited at this 
time point and concentration). (A) is modified from Alyea et al. (2008) with permission of Journal of Neurochemistry. Values are means and SEs; n = 24 for all com-
pounds. Points above the zero point line indicate a positive efflux of dopamine from the cells.
*p < 0.05 compared with control. #p < 0.05 compared with membrane, shown here for comparison with changes caused by BPA alone. 
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some of these xeno  biotics on dopamine efflux 
at low, environmentally relevant exposure lev-
els, comparing details of the functions at the 
cellular level with the presence and location of 
the cellular proteins involved (DAT and the 
different ERs).
On the basis of the dopamine efflux 
responses to these different estrogens (time 
courses and concentrations curves), we 
observed some similar patterns within sub-
classes of these chemicals. First, the group con-
sisting of E2 and DES (a non  steroidal synthetic 
pharmaceutical) caused rapid dopamine efflux, 
similarly peaking at 9–15 min. DES also has 
genomic actions similar to those of E2 (Arnold 
et al. 1996). However, the DES dose–response 
pattern at 9 min did not resemble that for E2 
at 9 min, so our studies show some differences 
between these compounds. Many studies in 
the past have used DES as a positive control 
for estrogenic responses because of the similar 
functional responses in many past animal and 
human studies (Fail et al. 1998; Fang et al. 
2001; Kwon et al. 2007; vom Saal et al. 1997; 
Yang et al. 2008). However, DES has a higher 
relative binding affinity for recombinant 
human ER-α and ER-β than does E2 (Nikov 
et al. 2000). In a previous study (Alyea et al. 
2008), we showed that although ER-α is the 
predominant media  tor of E2-mediated dop-
amine efflux, ER-β and GPR30 could have 
inhibitory roles. Therefore, differential DES 
(or other XE) binding to ER-β and GPR30 in 
our cell model could affect estrogen-mediated 
dopamine efflux.
NP and BPA both caused rapid dopa-
mine efflux within 5 min, followed by basal 
and then inhibitory responses. However, 
these XE-induced dopamine efflux patterns 
at 3–5 min differed significantly from the 
effects of E2 (which were inhibitory). This 
(and other examples from this series of experi-
ments) demon  strates that XEs, causing efflux 
in distinctly different temporal patterns com-
pared with E2, could cause altered patterns of 
response in combination. We have previously 
reported that some XEs also elicit responses 
differentially in pituitary cells (Bulayeva and 
Watson 2004; Wozniak et al. 2005), activating 
multiple temporally regulated kinase pathways 
that undoubtedly interact with one another, 
causing potential points of opposing or mis-
regulation. An alternate receptor-binding pro-
file for XEs could also modify the inclusion 
or extent of use of these multiple XE-induced 
signaling pathways. Such actions on a back-
ground of responses to physiologic levels of E2 
or other estrogens exemplify how these com-
pounds could disrupt the endocrine functions 
of humans and animals.
The third “use and structure class” of 
compounds that we studied were polychlori-
nated pesticides or their metabolites (DDE, 
endosulfan, and dieldrin). They caused rapid 
inhibition of dopamine efflux at the lower 
concentrations. Some organochlorine pesti-
cides, such as DDE and dieldrin, have been 
shown to cause increased dopamine, DAT, 
and vesicular monoamine transporter levels 
in vivo (Richardson et al. 2006; Sava et al. 
2007). In utero exposure to dieldrin leads 
to a delayed and enhanced vulnerability of 
dopamine neurons to the parkinsonism-
inducing neurotoxin MPTP (1-methyl-4-
phenyl-1,2,5,6-tetrahydro  pyridine), which 
is oxidized to MPP+ (1-methyl-4-phenyl-
pyridinium), the primary constituent of the 
herbicide cyperquat (Richardson et al. 2006). 
These effects are greater in males than in 
females (Richardson et al. 2006), suggesting a 
protective effect of physiologic estrogens.
Our extensive range of dose–response 
curves, at two time points for some compounds, 
revealed that E2 and all XEs that we studied can 
cause dopamine efflux changes at low, environ-
mentally relevant concentrations. We also show 
that at some of these rapid time points and low 
concentrations, these compounds caused sig-
nificant inhibition of dopa  mine efflux. Only a 
careful mapping of the response effects of com-
binations of these and other estrogenic com-
pounds (physiologic, pharmaceutical, industrial, 
agricultural, and dietary estrogens) will fully 
elucidate their aggregate potential for influenc-
ing dopamine efflux and thus contributing to 
adverse neurologic outcomes.
Although DDE alone did not cause dopa-
mine efflux, it caused potentiation of dopa-
mine efflux in the presence of physiologic 
levels of E2. Recently, Hatcher et al. (2008) 
reported that higher concentrations of DDE 
in vitro (although with documented lower lev-
els actually reaching the brain tissue) matched 
human post  mortem levels in Parkinson dis-
ease patients; these levels inhibit dopamine 
uptake and cause synaptosomal and vesicu-
lar release of dopamine without increasing 
intra  cellular oxidative stress. Increasing intra-
cellular dopamine concentrations (by deplet-
ing vesicular stores) can promote dopamine 
efflux by exchange diffusion (Fischer and Cho 
1979). It is possible that by combining DDE 
and E2 we are increasing intra  cellular dopa-
mine to the point that the mechanism shifts 
from efflux inhibition (or uptake) to efflux. 
This is only one of many possible mechanisms 
that should be explored for combinations of 
XEs and physiologic estrogens, or other XEs.
By examining the subcellular location 
of DAT and several ERs, we addressed how 
protein trafficking of important mediators 
might explain the functional effects of estro-
gens, including XEs, on dopamine transport. 
A mechanistic link can be made between 
the dopamine efflux functional state and the 
cellu  lar location of the ERs. Membrane ER-α 
either is increased or stays in the membrane 
when efflux occurs. However, at a concen-
tration and time point when BPA inhibits 
dopamine efflux, ER-α leaves the membrane. 
BPA-mediated dopamine efflux results in traf-
ficking of the inhibitory GPR30 from the 
plasma membrane, but under conditions 
where BPA inhibits dopamine efflux, all three 
ERs (both stimulatory and inhibitory of this 
response) leave the plasma membrane. The 
increased levels of membrane DAT caused 
by efflux-producing BPA treatments suggest 
that BPA-mediated dopamine efflux involves 
distinctly different intermediary mechanisms 
compared with E2. Compounds such as BPA 
that increase DAT numbers at the membrane 
have been reported to be pathological because 
increased DATs in the membrane leads to 
increased toxin susceptibility (McArthur et al. 
2007). Although both E2 and BPA cause 
dopamine efflux, E2 (which does not act by 
increasing DAT in the membrane) is reported 
to be neuro  protective (McEwen and Alves 
1999). Therefore, BPA could cause increased 
Figure 4. Effects of physiologic levels of E2 (10–9 M) combined with multiple concentrations of DDE or BPA 
measured by dopamine efflux assay. (A) E2 plus increasing concentrations of DDE during a 9-min dopamine 
efflux assay compared with E2-mediated dopamine efflux and DDE-mediated dopamine efflux. (B) E2 plus 
increasing concentrations of BPA during a 5-min dopamine efflux assay compared with E2-mediated dop-
amine efflux and BPA-mediated dopamine efflux. Values are means and SEs; numbers per treatment are as 
follows: E2, n = 18; BPA, n = 14; DDE, n = 14; DDE + E2, n = 15; BPA + E2, n = 15. Points above the zero point line 
indicate a positive efflux of dopa  mine from the cells. 
*p < 0.05 compared with control for combinations. #p < 0.05 compared with E2 treatment. ##p < 0.05 compared with control 
for E2. 
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vulnerability to dopamine-related diseases by 
increasing the level of functional DAT at the 
plasma membrane.
Women are abusing stimulants, such 
as amphetamine, methamphetamine, and 
cocaine, at an increasing rate. Although 
drug addiction and abuse rates involve many 
social factors, females display an association 
between sex steroid levels and drug behav-
ioral and neurochemical effects (Evans 2007). 
Amphetamines and methamphetamines also 
cause dopamine efflux via the DAT (Volz et al. 
2007). DAT displays sex differences; females 
have more DAT in the striatum than men 
(Mozley et al. 2001) although men experi-
ence higher amphetamine-stimulated striatal 
dopa  mine release (Munro et al. 2006), perhaps 
a function of having a lower baseline unaf-
fected by estrogens. Human females have been 
reported to experience increased euphoric feel-
ing from these drugs during the follicular phase 
of the menstrual cycle, which is correlated 
with the highest E2 levels (White et al. 2002). 
If XEs are capable of further increasing dop-
amine efflux by increasing functioning DAT 
in the membranes, then they could be further 
exacerbating the effects of both physiologic 
estrogens and drugs of abuse, perhaps with 
behavioral consequences. In rodent models, 
prenatal and neo  natal exposure to BPA leads 
to enhanced sensitivity to rewarding effects of 
methamphetamine (Suzuki et al. 2003) and 
morphine (Miyatake et al. 2006). It remains 
to be seen whether human XE exposure during 
specific developmental stages is associated with 
an increased vulnerability to drug addictions 
later in life, which might be especially rele-
vant to women. If XEs can act this potently via 
non  genomic signaling pathways, then the cur-
rent allowable and very prevalent contamina-
tion levels in our water and food supplies may 
lead to significant endocrine disruption and 
a variety of human diseases, including those 
affecting behavior.
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